Progression-free survival was significantly longer for those patients treated with bevacizumab plus chemotherapy than for those with chemotherapy alone ( median : @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- , respectively , stratified hazard ratio -LSB- HR -RSB- @ -LSB- @ % CI @-@ -RSB- , two-sided stratified log-rank p = @ ) .